» Articles » PMID: 23202302

Immune Dysfunction in Uremia—an Update

Overview
Journal Toxins (Basel)
Publisher MDPI
Specialty Toxicology
Date 2012 Dec 4
PMID 23202302
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Kidney dysfunction leads to disturbed renal metabolic activities and to impaired glomerular filtration, resulting in the retention of toxic solutes affecting all organs of the body. Cardiovascular disease (CVD) and infections are the main causes for the increased occurrence of morbidity and mortality among patients with chronic kidney disease (CKD). Both complications are directly or indirectly linked to a compromised immune defense. The specific coordinated roles of polymorphonuclear leukocytes (PMNLs), monocytes/macrophages, lymphocytes and antigen-presenting cells (APCs) in maintaining an efficient immune response are affected. Their normal response can be impaired, giving rise to infectious diseases or pre-activated/primed, leading to inflammation and consequently to CVD. Whereas the coordinated removal via apoptosis of activated immune cells is crucial for the resolution of inflammation, inappropriately high apoptotic rates lead to a diminished immune response. In uremia, the balance between pro- and anti-inflammatory and between pro- and anti-apoptotic factors is disturbed. This review summarizes the interrelated parameters interfering with the immune response in uremia, with a special focus on the non-specific immune response and the role of uremic toxins.

Citing Articles

Lessons for the clinical nephrologist: a rare presentation of extrapulmonary tuberculosis in a hemodialysis patient.

Karur A, Kumar P, Nayak-Rao S J Nephrol. 2025; .

PMID: 39903383 DOI: 10.1007/s40620-024-02183-4.


Profiling oxidative stress markers and cardiovascular complications in chronic kidney disease patients supplemented with vitamin E.

Azouaou L, Adnane M, Chabati O, Arab M, Chahine T, Chader H Arch Med Sci Atheroscler Dis. 2024; 9:e183-e192.

PMID: 39559176 PMC: 11571200. DOI: 10.5114/amsad/192427.


The Oral Health Condition of Patients on Hemodialysis at a Tertiary Healthcare Facility in Eastern Nepal.

Joshi N, Shrestha A, Bhagat T, Agrawal S, Chhetri R Int J Dent. 2024; 2024:3776702.

PMID: 38375436 PMC: 10876310. DOI: 10.1155/2024/3776702.


Leukopenia in autosomal dominant polycystic kidney disease: a single-center cohort of kidney transplant candidates with post-transplantation follow-up.

Schellekens P, Van Loon E, Coemans M, Meyts I, Vennekens R, Kuypers D Clin Kidney J. 2023; 16(12):2578-2586.

PMID: 38046014 PMC: 10689124. DOI: 10.1093/ckj/sfad165.


Residual Kidney Function and Cause-Specific Mortality Among Incident Hemodialysis Patients.

Okazaki M, Obi Y, Shafi T, Rhee C, Kovesdy C, Kalantar-Zadeh K Kidney Int Rep. 2023; 8(10):1989-2000.

PMID: 37849997 PMC: 10577493. DOI: 10.1016/j.ekir.2023.07.020.


References
1.
Saemann M, Weichhart T, Horl W, Zlabinger G . Tamm-Horsfall protein: a multilayered defence molecule against urinary tract infection. Eur J Clin Invest. 2005; 35(4):227-35. DOI: 10.1111/j.1365-2362.2005.01483.x. View

2.
Carrero J, Stenvinkel P . Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol. 2009; 4 Suppl 1:S49-55. DOI: 10.2215/CJN.02720409. View

3.
Sengoelge G, Sunder-Plassmann G, Horl W . Potential risk for infection and atherosclerosis due to iron therapy. J Ren Nutr. 2005; 15(1):105-10. DOI: 10.1053/j.jrn.2004.09.018. View

4.
Hutchison C, Harding S, Hewins P, Mead G, Townsend J, Bradwell A . Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3(6):1684-90. PMC: 2572283. DOI: 10.2215/CJN.02290508. View

5.
Gordon J, Smith J . Immunoglobulin synthesis by neoplastic B lymphocytes: free light chain synthesis as a marker of B cell differentiation. J Immunol. 1980; 125(5):2177-81. View